Memorial Sloan-Kettering Cancer Center

Bridge Medicines appoints William J. Polvino chief executive officer

Tuesday, March 28, 2017

Bridge Medicines, a drug discovery company focused on advancing promising early technologies from concept to clinic, announced the appointment of William J. Polvino, M.D., as chief executive officer (CEO). In conjunction, Kathleen Metters, Ph.D., who served as the interim CEO upon the establishment of Bridge Medicines in October 2016, will continue to have an operating role within Bridge Medicines, and will Chair the Scientific Advisory Board.

[Read More]

Personalized medicine impacting study conduct

Sunday, January 1, 2017

As the analysis of genetic data is fast becoming a significant part of clinical research programs, both to enroll study participants and understand how drugs work, investigative sites are increasingly asked to collect genetic samples and conduct genetic screenings for clinical trials.

[Read More]

Bridge Medicines launched to advance early technologies

Wednesday, November 2, 2016

Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.

[Read More]

Fate Therapeutics, Memorial Sloan-Kettering partner on T-Cell Immunotherapies

Tuesday, September 13, 2016

Fate Therapeutics, a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, has announced a partnership with Memorial Sloan-Kettering Cancer Center for the development of off-the-shelf T-cell product candidates using engineered pluripotent cell lines. Research and development activities under the multi-year collaboration will be led by Michel Sadelain, M.D., Ph.D., director of the Center for Cell Engineering and the Stephen and Barbara Friedman Chair at Memorial Sloan-Kettering Cancer Center.

[Read More]

Juno partners Memorial Sloan Kettering and Eureka Therapeutics

Tuesday, August 9, 2016

Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, has entered into an exclusive license agreement with Memorial Sloan-Kettering Cancer Center (MSK) and Eureka Therapeutics for a novel, fully-human binding domain targeting B-cell maturation antigen (BCMA), along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma.

[Read More]